Cargando…

Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction

BACKGROUND: Treatment with tumour necrosis factor inhibitors (TNF-i) plus methotrexate (MTX), but not MTX monotherapy alone, inhibits joint damage progression even at higher levels of disease activity. Such disassociation of disease activity and structural damage has not been shown for biological ag...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smolen, Josef S, Avila, José C Martinez, Aletaha, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Group 2011
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3329225/ https://www.ncbi.nlm.nih.gov/pubmed/22121130 http://dx.doi.org/10.1136/annrheumdis-2011-200395

Ejemplares similares

Developments in the clinical understanding of rheumatoid arthritis
por: Smolen, Josef S, et al.
Publicado: (2009)

Laboratory and febrile features after joint surgery in patients with rheumatoid arthritis treated with tocilizumab
por: Hirao, M, et al.
Publicado: (2008)

Value of self-performed joint counts in rheumatoid arthritis patients near remission
por: Radner, Helga, et al.
Publicado: (2012)

Association of the 6q23 region with the rate of joint destruction in rheumatoid arthritis
por: Scherer, Hans Ulrich, et al.
Publicado: (2009)

Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis
por: Lopez-Romero, Pedro, et al.
Publicado: (2022)

Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials
por: Aletaha, Daniel, et al.
Publicado: (2015)

Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy
por: Mori, Shunsuke, et al.
Publicado: (2013)

Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs
por: Radner, Helga, et al.
Publicado: (2014)

Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients
por: Koike, Takao, et al.
Publicado: (2011)

Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis
por: Mori, Shunsuke, et al.
Publicado: (2012)

Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial
por: Burmester, Gerd R, et al.
Publicado: (2016)

Large joints are progressively involved in rheumatoid arthritis irrespective of rheumatoid factor status—results from the early rheumatoid arthritis study
por: Zhao, Sizheng Steven, et al.
Publicado: (2021)

Physical function continues to improve when clinical remission is sustained in rheumatoid arthritis patients
por: Radner, Helga, et al.
Publicado: (2015)

Evaluation of different methods used to assess disease activity in rheumatoid arthritis: analyses of abatacept clinical trial data
por: Dougados, M, et al.
Publicado: (2008)

Role of LIGHT in the pathogenesis of joint destruction in rheumatoid arthritis
por: Sabokbar, Afsie, et al.
Publicado: (2017)

Inflammation and Bone Metabolism in Rheumatoid Arthritis: Molecular Mechanisms of Joint Destruction and Pharmacological Treatments
por: Maeda, Kazuhiro, et al.
Publicado: (2022)

Role of clinical and biochemical inflammation in structural progression of patients with psoriatic arthritis
por: Borst, Carina, et al.
Publicado: (2021)

Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate
por: Wells, G, et al.
Publicado: (2008)

Clinical joint inactivity predicts structural stability in patients with established rheumatoid arthritis
por: Gärtner, M, et al.
Publicado: (2016)

Power Doppler ultrasonography is useful for assessing disease activity and predicting joint destruction in rheumatoid arthritis patients receiving tocilizumab—preliminary data
por: Hama, Maasa, et al.
Publicado: (2011)

Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years
por: Rahman, Mahboob U, et al.
Publicado: (2011)

The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?
por: Smolen, Josef S, et al.
Publicado: (2008)

Evidence for treating rheumatoid arthritis to target: results of a systematic literature search
por: Schoels, Monika, et al.
Publicado: (2010)

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
por: Jones, G, et al.
Publicado: (2010)

Editorial: Immunomodulatory Functions of Fibroblast-like Synoviocytes in Joint Inflammation and Destruction during Rheumatoid Arthritis
por: Xu, Hanshi, et al.
Publicado: (2020)

Gene therapy in rheumatoid arthritis: how to target joint destruction?
por: Pap, Thomas, et al.
Publicado: (1999)

Remission by composite scores in rheumatoid arthritis: are ankles and feet important?
por: Kapral, Theresa, et al.
Publicado: (2007)

Application of the 2010 ACR/EULAR classification criteria in patients with very early inflammatory arthritis: analysis of sensitivity, specificity and predictive values in the SAVE study cohort
por: Biliavska, Iuliia, et al.
Publicado: (2013)

The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy
por: Conaghan, Philip G, et al.
Publicado: (2014)

Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition
por: Schoels, M., et al.
Publicado: (2017)

Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis
por: Strand, Vibeke, et al.
Publicado: (2018)

Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire
por: Haraoui, Boulos, et al.
Publicado: (2011)

Analysis of gene expression in rheumatoid arthritis and related conditions offers insights into sex-bias, gene biotypes and co-expression patterns
por: Platzer, Alexander, et al.
Publicado: (2019)

Methotrexate in rheumatoid arthritis is frequently effective, even if re-employed after a previous failure
por: Kapral, Theresa, et al.
Publicado: (2006)

Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate
por: Smolen, Josef S, et al.
Publicado: (2013)

Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA)
por: Bingham, Clifton O, et al.
Publicado: (2015)

Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis
por: Gabay, Cem, et al.
Publicado: (2016)

Review of tocilizumab in the treatment of rheumatoid arthritis
por: Okuda, Yasuaki
Publicado: (2008)

Tocilizumab in the treatment of rheumatoid arthritis and beyond
por: Shetty, Anjali, et al.
Publicado: (2014)

Tocilizumab: A Review in Rheumatoid Arthritis
por: Scott, Lesley J.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_vnuiioeeqejdn2c3hvm6gsbfrh